ACP-105 was characterized in laboratory and animal work. Published studies do not demonstrate that it improves human performance, treats injury or has an acceptable long-term safety profile.
Key points
- Discovery studies measure receptor selectivity and animal outcomes, not clinical benefit.
- A study involving irradiated mice assessed motor behaviour and memory, not sport performance.
- There is no established human dose, exposure profile or recovery timeline.
What the literature shows
Schlienger and colleagues described a class of nonsteroidal selective androgen receptor modulators and evaluated pharmacological activity in experimental models. Those tests are useful for compound discovery but are not clinical trials.
Dayger and colleagues tested ACP-105 in female mice after irradiation. The narrow experimental setting should not be generalized to healthy people seeking muscle gain or neurological protection.
What remains unknown
- No published randomized trial establishes efficacy or risk in people.
- Long-term endocrine, liver and cardiovascular outcomes remain uncharacterized.
Safety and monitoring implications
- Androgen receptor activity makes hormonal consequences plausible even when advertising describes the compound as selective.
- A product sold under a research-chemical label is not equivalent to a quality-controlled trial preparation.
Cited literature
- 1.Schlienger N, Lund BW, Pawlas J, et al. (2009). Synthesis, structure–activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. Journal of Medicinal Chemistry. Find on PubMed
- 2.Dayger CA, Villasana LE, Pfankuch T, et al. (2011). Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice. Brain Research. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying ACP-105 in Australia: what to check first
APEDRA does not sell ACP-105 or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.